ARPC1B+ がん幹細胞を標的とし,臓がんをジェムシタビン治療に敏感にする
Yang Wu1, Jianpeng Zhang2, Weixiong Zhu3
1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Cell proliferation
|September 3, 2025
まとめ
CK-636はゲムシタビン耐性臓がん幹細胞 (CSCs) を標的とすることができる. ゲムシタビンとCK-636の併用療法では,抗腫瘍効果が優れ,薬剤耐性を克服することが示された.
科学分野:
- 腫瘍学
- 癌 生物学
- 薬物の発見
背景:
- ARPC1Bを発現するゲムシタビン耐性がん幹細胞 (CSCs) が宿っている.
- ゲムシタビン耐性を克服する戦略を策定することは,患者の治療結果を改善するために極めて重要です.
関連する概念動画
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K